Table 1 Criteria for registry participants

Inclusion

• Patients with a diagnosis of chronic hypoparathyroidism and with a duration of ≥6 months

 – Adult patients aged ≥18 years who are receiving conventional therapy, conventional therapy plus rhPTH(1-84), or rhPTH(1-84) alone

 – Pediatric patients aged <18 years who are receiving conventional therapy, conventional therapy plus rhPTH(1-84), or rhPTH(1-84) alone

Exclusion

• Patients or legally authorized representatives unable to provide informed consent

• Patients using rhPTH(1-34), or used rhPTH(1-34) for >2 years and in the past 3 months

• Patients currently enrolled in an interventional clinical study whether or not the study is related to hypoparathyroidism^a

• History of hypoparathyroidism resulting from a known activating mutation in the CASR gene

• History of hypoparathyroidism resulting from impaired responsiveness to PTH (pseudohypoparathyroidism)